14th International Headache Congress: Clinical Highlights

Authors

  • Todd J. Schwedt MD,

    1. From the Washington University Headache Center, Washington University in St. Louis School of Medicine, St. Louis, MO, USA (T.J. Schwedt); Jefferson Headache Center, Jefferson Medical College, Philadelphia, PA, USA (S.D. Silberstein).
    Search for more papers by this author
  • Stephen D. Silberstein MD

    1. From the Washington University Headache Center, Washington University in St. Louis School of Medicine, St. Louis, MO, USA (T.J. Schwedt); Jefferson Headache Center, Jefferson Medical College, Philadelphia, PA, USA (S.D. Silberstein).
    Search for more papers by this author

  • Disclosures: Todd Schwedt was a site investigator in the Allergan-sponsored botulinum toxin PREEMPT trial and he receives research support from Merck.

  • Stephen Silberstein is on the advisory panel of and receives honoraria from AGA, Allergan, Amgen, Capnia, Coherex, Colucid, Cydex, GlaxoSmithKline, Lilly, MAP, Medtronic, Merck, Minster, Neuralieve, NINDS, NuPathe, Pfizer, St. Jude Medical, and Valeant. He is on the speakers’ bureau of and receives honoraria from Endo Pharmaceuticals, GlaxoSmithKline, and Merck. He serves as a consultant for and receives honoraria from Novartis and Amgen. His employer receives research support from AGA, Allergan, Boston Scientific, Capnia, Coherex, Endo Pharmaceuticals, GlaxoSmithKline, Lilly, MAP, Medtronic, Merck, NINDS, NuPathe, St. Jude Medical, and Valeant Pharmaceuticals.

Todd J. Schwedt, Washington University Headache Center, Washington University in St. Louis School of Medicine, 660 South Euclid Ave, Box #8111, St. Louis, MO 63110, USA.

Abstract

The 14th International Headache Congress was held in Philadelphia in September 2009. During the Congress, many important basic, translational, and patient-oriented research studies were presented. In this and an accompanying manuscript, the work that has been deemed to be among the most innovative and significant is summarized. This manuscript discusses the best clinical research, while the accompanying manuscript summarizes the top basic science research. Here, we provide background and summarize Congress presentations on novel agents for migraine treatment, botulinum toxin therapy for chronic migraine, new methods for administration of headache medications, and nerve stimulation for the treatment of medically refractory headaches.

Ancillary